In conclusion, we have presented evidence that SPIN1, a novel target of the miR-148/152 family, is upregulated in drug-resistant breast cancer cells and tissues and confers Adriamycin resistance by upregulating drug metabolizing enzymes and transporter in breast cancer. Here, SPIN1 is linked to breast carcinoma.